Solution

AAV Integration Site Analysis: Safeguard Against Insertional Mutagenesis Risks

About the Solution

Gene therapy employs vectors such as Adeno-Associated Virus (AAV) and lentivirus to deliver therapeutic genes into cells, but each vector has distinct integration characteristics that affect their safety and efficacy. Understanding these integration patterns is essential for optimizing therapeutic applications and ensuring patient safety. Our comprehensive guide offers strategic insights for choosing the most suitable vector, while detailing our AAV Integration Site Analysis service to assist you in making informed decisions.

At CD Genomics, we offer advanced AAV Integration Site Analysis services that elucidate the genomic integration patterns of AAV vectors. Utilizing hybrid-capture-based target enrichment sequencing (TES), our service precisely identifies and characterizes integration sites within the host genome. This analysis enhances safety evaluations by revealing potential insertional mutagenesis risks and supports the optimization of gene therapy strategies. Our comprehensive and accurate results are tailored to meet your specific research needs, ensuring that your gene therapy applications are both safe and effective.

For more information about our services, including but not limited to those listed:

Download the Solution

* Name:
* Email Address:
* Verification code:
Verification code

CD Genomics needs the contact information you provide to us in order to contact you about our products and services and other content that may be of interest to you.

By clicking below, you consent to the storage and processing of the personal information submitted above by CD Genomcis to provide the content you have requested.

For any other type of support, feel free to contact us
1-631-338-8059 |